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Background:  Nicorandil is a hybrid compound of adenosine triphosphate-sensitive potassium channel opener and nitric oxide donor. Matrix 
metalloproteinases (MMPs) are involved in the regulation of cardiac extracellular matrix metabolism. We investigated the effect of intravenous 
nicorandil therapy on serum levels of MMP-2 and left ventricular (LV) remodeling in patients with acute heart failure syndromes (AHFS).
Methods:  A total of 20 consecutive patients (age 74±10 years, LV ejection fraction 48±13%) with AHFS admitted at our hospital were analyzed. 
Plasma brain natriuretic peptide (BNP) and serum MMP-2 levels were examined on admission, 2 and 14 days after admission. Echocardiography 
was performed on admission, 2, 14 days and 6 months after admission. Patients were divided into two groups based on the intravenous treatment 
for AHFS, nicorandil treated group (n=10) or nitroglycerine treated group (n=10). Intravenous injection of diuretics was permitted. We excluded 
patients received inotropic agents.
Results:  Plasma BNP and serum MMP-2 levels were gradually decreased in proportion to the severity of AHFS during hospitalization in both 
groups. From at the time of admission to 2 days, repeated measurements ANOVA showed that treatment with nicorandil tended to affect plasma 
BNP levels (884.8±463.2pg/ml, 201.1±112.8pg/ml, respectively in the nicorandil group; 833.0±532.4pg/ml, 438.0±563.8pg/ml, respectively in 
the nitroglycerine group: p=0.0696), and significantly affected serum MMP-2 levels (1545.0±319.3ng/ml, 911.6±350.9ng/ml, respectively in the 
nicorandil group; 1341.7±342.8ng/ml, 1035.9±272.8ng/ml, respectively in the nitroglycerine group: p=0.0049). From at the time of admission to 6 
months, tissue doppler imaging index E/E’ ratio was significantly decreased in the nicorandil group (10.26±2.90 to 7.46±1.50, p=0.0425), but not 
in the nitroglycerine group (10.33±3.44 to 10.43±4.34, p=0.6781).
Conclusions:  Intravenous nicorandil therapy reduces serum MMP-2 levels and might beneficially affect LV remodeling in patients with AHFS.
